Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials.
Elizabeth A RaetzPaola ReboraValentino ConterMartin SchrappeMeenakshi DevidasGabriele EscherichChihaya ImaiBarbara De MoerlooseKjeld SchmiegelowMelissa A BurnsSarah ElitzurRob PietersAndishe AttarbaschiAllen Eng-Juh YeohChing-Hong PuiJan StaryGunnar CarioNicole BodmerAnthony V MoormanBarbara BuldiniAjay VoraMaria Grazia ValsecchiPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Outcomes for patients age 21 years and younger with T-ALL and IF have improved in the contemporary treatment era with a DFS benefit among those undergoing HSCT in CR1. However, outcomes still lag considerably behind those who achieve remission at EOI, warranting investigation of new treatment approaches.